The DOI matches its Crossref record; 1 of the 1 references it cites were found in a registry or an index.
Direct, Differential Effects of Tamoxifen, 4-Hydroxytamoxifen, and Raloxifene on Cardiac Myocyte Contractility and Calcium Handling
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“This antibody has been highly used in the field by many groups to track PKA-dependent phosphorlyation status of cTnI in cardiac muscle11–15.”
From Cytoplasmic nucleic acid-based XNAs directly enhance live cardiac cell function by a Ca2+ cycling-independent mechanism via the sarcomere (2019) · cites this paper as [12]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Hirrlinger, P. G., Scheller, A., Braun, C., Hirrlinger, J., & Kirchhoff, F. (2006) · Glia · doi:10.1002/glia.20342 · Cited by 200
Research works printed but not linked: 42
- A Umar, 2012, Future directions in cancer prevention, Nat Rev Cancer, 12, 835, 10.1038/nrc3397 · DOI · Paper page
- A Michalski, 2010, The addition of high-dose tamoxifen to standard radiotherapy does not improve the survival of patients with diffuse intrinsic pontine glioma, J Neuro Oncol, 100, 81, 10.1007/s11060-010-0141-9 · doi:10.1007/s11060-010-0141-9
- P Tang, 2006, A phase II study of carboplatin and chronic high-dose tamoxifen in patients with recurrent malignant glioma, J Neuro Oncol, 78, 311, 10.1007/s11060-005-9104-y · DOI
- IF Pollack, 1997, A phase I study of high-dose tamoxifen for the treatment of refractory malignant gliomas of childhood, Clin Cancer Res, 3, 1109
- S Patel, 2012, Phase I clinical trial assessing temozolomide and tamoxifen with concomitant radiotherapy for treatment of high-grade glioma, Int J Radiat Oncol Biol Phys, 82, 739, 10.1016/j.ijrobp.2010.12.053 · doi:10.1016/j.ijrobp.2010.12.053
- NS Stuart, 1992, High-dose tamoxifen as an enhancer of etoposide cytotoxicity. Clinical effects and in vitro assessment in p-glycoprotein expressing cell lines, Br J Cancer, 66, 833, 10.1038/bjc.1992.369 · DOI
- DL Trump, 1992, High-dose oral tamoxifen, a potential multidrug-resistance-reversal agent: phase I trial in combination with vinblastine, J Natl Cancer Inst, 84, 1811, 10.1093/jnci/84.23.1811 · DOI · Paper page
- CA O'Brian, 1985, Inhibition of protein kinase C by tamoxifen, Cancer Res, 45, 2462
- E Berman, 1991, Effect of tamoxifen on cell lines displaying the multidrug-resistant phenotype, Blood, 77, 818, 10.1182/blood.V77.4.818.818 · doi:10.1182/blood.v77.4.818.818
- L Slovacek, 2008, Tamoxifen-induced QT interval prolongation, J Clin Pharm Ther, 33, 453, 10.1111/j.1365-2710.2008.00928.x · doi:10.1111/j.1365-2710.2008.00928.x
- S Beca, 2008, Inhibition of a cardiac sarcoplasmic reticulum chloride channel by tamoxifen, Pflugers Arch, 457, 121, 10.1007/s00424-008-0510-9 · DOI
- D Ponce-Balbuena, 2009, Tamoxifen inhibits inward rectifier K+ 2.x family of inward rectifier channels by interfering with phosphatidylinositol 4,5-bisphosphate-channel interactions, J Pharmacol Exp Ther, 331, 563, 10.1124/jpet.109.156075 · DOI
- D Ponce-Balbuena, 2010, Tamoxifen inhibits cardiac ATP-sensitive and acetylcholine-activated K+ currents in part by interfering with phosphatidylinositol 4,5-bisphosphate-channel interaction, J Pharmacol Sci, 113, 66, 10.1254/jphs.10024FP · DOI
- V Vasioukhin, 1999, The magical touch: genome targeting in epidermal stem cells induced by tamoxifen application to mouse skin, Proc Natl Acad Sci U S A, 96, 8551, 10.1073/pnas.96.15.8551 · DOI · Paper page
- JJ McCarthy, 2012, Inducible Cre transgenic mouse strain for skeletal muscle-specific gene targeting, Skelet Muscle, 2, 8, 10.1186/2044-5040-2-8 · DOI · Paper page
- ME Gómez-Casati, 2010, Cell-specific inducible gene recombination in postnatal inner ear supporting cells and glia, J Assoc Res Otolaryngol, 11, 19, 10.1007/s10162-009-0191-x · DOI
- DS Sohal, 2001, Temporally regulated and tissue-specific gene manipulations in the adult and embryonic heart using a tamoxifen-inducible Cre protein, Circ Res, 89, 20, 10.1161/hh1301.092687 · DOI · Paper page
- TD Littlewood, 1995, A modified oestrogen receptor ligand-binding domain as an improved switch for the regulation of heterologous proteins, Nucleic Acids Res, 23, 1686, 10.1093/nar/23.10.1686 · DOI · Paper page
- Y Zhang, 1996, Inducible site-directed recombination in mouse embryonic stem cells, Nucleic Acids Res, 24, 543, 10.1093/nar/24.4.543 · DOI · Paper page
- PS Danielian, 1993, Identification of residues in the estrogen receptor that confer differential sensitivity to estrogen and hydroxytamoxifen, Mol Endocrinol, 7, 232
- WB Pratt, 1990, Interaction of hsp90 with steroid receptors: organizing some diverse observations and presenting the newest concepts, Mol Cell Endocrinol, 74, C69, 10.1016/0303-7207(90)90198-H · DOI
- J Davis, 2012, Lost in transgenesis: a user's guide for genetically manipulating the mouse in cardiac research, Circ Res, 111, 761, 10.1161/CIRCRESAHA.111.262717 · DOI
- A Buerger, 2006, Dilated cardiomyopathy resulting from high-level myocardial expression of Cre-recombinase, J Card Fail, 12, 392, 10.1016/j.cardfail.2006.03.002 · DOI
- N Koitabashi, 2009, Avoidance of transient cardiomyopathy in cardiomyocyte-targeted tamoxifen-induced MerCreMer gene deletion models, Circ Res, 105, 12, 10.1161/CIRCRESAHA.109.198416 · DOI · Paper page
- K Hougen, 2010, Cre-loxP DNA recombination is possible with only minimal unspecific transcriptional changes and without cardiomyopathy in Tg(alphaMHC-MerCreMer) mice, Am J Physiol Heart Circ Physiol, 299, H1671, 10.1152/ajpheart.01155.2009 · DOI
- GM Kravtsov, 2007, Altered Ca(2+) handling by ryanodine receptor and Na(+)-Ca(2+) exchange in the heart from ovariectomized rats: role of protein kinase A, Am J Physiol Cell Physiol, 292, C1625, 10.1152/ajpcell.00368.2006 · DOI
- E Filice, 2011, Crucial role of phospholamban phosphorylation and S-nitrosylation in the negative lusitropism induced by 17β-estradiol in the male rat heart, Cell Physiol Biochem, 28, 41, 10.1159/000331712 · DOI
- J Kulpa, 2012, Rapid changes in cardiac myofilament function following the acute activation of estrogen receptor-alpha, PLOS ONE, 7, e41076, 10.1371/journal.pone.0041076 · DOI
- W Wang, 2013, Noncanonical EF-hand motif strategically delays Ca2+ buffering to enhance cardiac performance, Nat Med, 19, 305, 10.1038/nm.3079 · DOI · Paper page
- K Sideras, 2010, Coprescription of tamoxifen and medications that inhibit CYP2D6, J Clin Oncol, 28, 2768, 10.1200/JCO.2009.23.8931 · DOI
- BS Katzenellenbogen, 1984, Bioactivities, estrogen receptor interactions, and plasminogen activator-inducing activities of tamoxifen and hydroxy-tamoxifen isomers in MCF-7 human breast cancer cells, Cancer Res, 44, 112
- E Filice, 2009, A new membrane G protein-coupled receptor (GPR30) is involved in the cardiac effects of 17beta-estradiol in the male rat, J Physiol Pharmacol, 60, 3
- J Duan, 2004, Comparison of cardiac contractile and intracellular Ca2+ response between estrogen and phytoestrogen alpha-zearalanol in ventricular myocytes, Endocrine, 24, 33, 10.1385/ENDO:24:1:033 · doi:10.1385/endo:24:1:033
- J He, 2003, Tamoxifen inhibits Na+ and K+ currents in rat ventricular myocytes, Am J Physiol Heart Circ Physiol, 285, H661, 10.1152/ajpheart.00686.2002 · DOI
- J Song, 1996, Tamoxifen (estrogen antagonist) inhibits voltage-gated calcium current and contractility in vascular smooth muscle from rats, J Pharmacol Exp Ther, 277, 1444
- ND Ullrich, 2008, Genomic deletion of estrogen receptors ERalpha and ERbeta does not alter estrogen-mediated inhibition of Ca2+ influx and contraction in murine cardiomyocytes, Am J Physiol Heart Circ Physiol, 294, H2421, 10.1152/ajpheart.01225.2007 · DOI
- ME Kargacin, 2000, Tamoxifen inhibits Ca2+ uptake by the cardiac sarcoplasmic reticulum, Pflugers Arch, 440, 573, 10.1007/s004240000318 · DOI
- L Xie, 2007, In silico elucidation of the molecular mechanism defining the adverse effect of selective estrogen receptor modulators, PLOS Comput Biol, 3, e217, 10.1371/journal.pcbi.0030217 · DOI
- R Liew, 2004, Raloxifene acutely suppresses ventricular myocyte contractility through inhibition of the L-type calcium current, Br J Pharmacol, 142, 89, 10.1038/sj.bjp.0705736 · DOI
- B Lewartowski, 1990, Net Ca2+ influx and sarcoplasmic reticulum Ca2+ uptake in resting single myocytes of the rat heart: comparison with guinea-pig, J Mol Cell Cardiol, 22, 1221, 10.1016/0022-2828(90)90059-B · DOI
- M Furlanut, 2007, Tamoxifen and its main metabolites serum and tissue concentrations in breast cancer women, Ther Drug Monit, 29, 349, 10.1097/FTD.0b013e318067ded7 · doi:10.1097/ftd.0b013e318067ded7
- ER Kisanga, 2003, Tamoxifen administration and metabolism in nude mice and nude rats, J Steroid Biochem Mol Biol, 84, 361, 10.1016/S0960-0760(03)00051-7 · DOI
Cited by
Tripathy, D., Im, S.-A., Colleoni, M., Franke, F., Bardia, A., Harbeck, N., Hurvitz, S. A., Chow, L., Sohn, J., Lee, K. S., et al. (2018) · The Lancet Oncology · doi:10.1016/s1470-2045(18)30292-4 · Cited by 1,025
Multi-organ system for the evaluation of efficacy and off-target toxicity of anticancer therapeutics
McAleer, C. W., Long, C. J., Elbrecht, D., Sasserath, T., Bridges, L. R., Rumsey, J. W., Martin, C., Schnepper, M., Wang, Y., Schuler, F., et al. (2019) · Science Translational Medicine · doi:10.1126/scitranslmed.aav1386 · Cited by 199
Tamoxifen in men: a review of adverse events
Wibowo, E., Pollock, P. A., Hollis, N., & Wassersug, R. J. (2016) · Andrology · doi:10.1111/andr.12197 · Cited by 97
Ngan, N. T. T., Mai, N. T. H., Tung, N. L. N., Lan, N. P. H., Tai, L. T. H., Phu, N. H., Chau, N. V. V., Binh, T. Q., Hung, L. Q., Beardsley, J., et al. (2019) · Wellcome Open Research · doi:10.12688/wellcomeopenres.15010.1 · Cited by 28
Thompson, B. R., Soller, K. J., Vetter, A., Yang, J., Veglia, G., Bowser, M. T., & Metzger, J. M. (2019) · Journal of Molecular and Cellular Cardiology · doi:10.1016/j.yjmcc.2019.02.016 · Cited by 2
Self-citation
Metadata
- Authors
- Asp, M. L., Martindale, J. J., & Metzger, J. M.
- Venue
- PLoS ONE
- Publisher
- Public Library of Science (PLoS)
- Published
- 2013-10-24
- Volume
- 8
- Issue
- 10
- Pages
- e78768
- ISSN
- 1932-6203
- Cited by
- 32
- References
- 1
- Language
- en
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.